GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for ...

GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...

GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on iTeos Therapeutics (ITOS – Research Report) today and set a price ...

Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...